CO5271694A1 - BETA DI-REPLACED INHIBITORS OF METALOPROTEASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCEDURES FOR APPLICATION - Google Patents
BETA DI-REPLACED INHIBITORS OF METALOPROTEASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCEDURES FOR APPLICATIONInfo
- Publication number
- CO5271694A1 CO5271694A1 CO00078367A CO00078367A CO5271694A1 CO 5271694 A1 CO5271694 A1 CO 5271694A1 CO 00078367 A CO00078367 A CO 00078367A CO 00078367 A CO00078367 A CO 00078367A CO 5271694 A1 CO5271694 A1 CO 5271694A1
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutical compositions
- compounds
- inhibitors
- metaloproteases
- beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
La presente invención se relaciona con compuestos que son inhibidores de las metaloproteasas y que son eficaces en el tratamiento de condiciones que se caracterizan por la actividad excesiva de estas enzimas. En particular, los compuestos tienen una estructura según la siguiente fórmula (I): <EMI FILE="00078367_1" ID="1" IMF=JPEG >Donde R1, R2, R3, R4, R5, R6, G y Z tienen los significados que se describen en la especificación. Esta invención también incluye, isómeros, ópticos, diastereómeros y enantiómeros de la Fórmula I, y sales farmacéuticamente aceptables, amidas biohidrolizables, ésteres, e imidas de éstos. Además se describen composiciones farmacéuticas que comprenden estos compuestos, y procedimientos de tratar enfermedades relacionadas a las metaloproteasas utilizando los compuestos o las composiciones farmacéuticas.The present invention relates to compounds that are inhibitors of metalloproteases and that are effective in the treatment of conditions characterized by the excessive activity of these enzymes. In particular, the compounds have a structure according to the following formula (I): <EMI FILE = "00078367_1" ID = "1" MFI = JPEG> Where R1, R2, R3, R4, R5, R6, G and Z have the meanings described in the specification. This invention also includes isomers, optics, diastereomers and enantiomers of Formula I, and pharmaceutically acceptable salts, biohydrolysable amides, esters, and imides thereof. In addition, pharmaceutical compositions comprising these compounds, and methods of treating diseases related to metalloproteases using the compounds or pharmaceutical compositions are described.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15932099P | 1999-10-14 | 1999-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5271694A1 true CO5271694A1 (en) | 2003-04-30 |
Family
ID=22572063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00078367A CO5271694A1 (en) | 1999-10-14 | 2000-10-13 | BETA DI-REPLACED INHIBITORS OF METALOPROTEASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCEDURES FOR APPLICATION |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1224171A1 (en) |
JP (1) | JP2003519100A (en) |
KR (1) | KR20020038951A (en) |
CN (1) | CN1379762A (en) |
AU (1) | AU8014500A (en) |
BR (1) | BR0014759A (en) |
CA (1) | CA2386485A1 (en) |
CO (1) | CO5271694A1 (en) |
CZ (1) | CZ20021161A3 (en) |
HU (1) | HUP0203118A3 (en) |
IL (1) | IL148893A0 (en) |
MA (1) | MA25561A1 (en) |
MX (1) | MXPA02003811A (en) |
NO (1) | NO20021748L (en) |
NZ (1) | NZ517983A (en) |
PE (1) | PE20011003A1 (en) |
PL (1) | PL355764A1 (en) |
SK (1) | SK5082002A3 (en) |
TR (1) | TR200200977T2 (en) |
WO (1) | WO2001027084A1 (en) |
ZA (1) | ZA200202207B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003080042A1 (en) * | 2002-03-27 | 2003-10-02 | Shionogi & Co., Ltd. | Decomposition inhibitor for extracellular matrix of cartilage |
AU2003304456A1 (en) | 2002-12-23 | 2005-03-16 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
WO2005061459A1 (en) | 2003-12-04 | 2005-07-07 | Wyeth | Biaryl sulfonamides and methods for using same |
RU2006123559A (en) | 2003-12-04 | 2008-01-10 | Уайт (Us) | BIARILSULPHONAMIDES AS MMP INHIBITORS |
US7576222B2 (en) | 2004-12-28 | 2009-08-18 | Wyeth | Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase |
DE602005020367D1 (en) * | 2005-06-29 | 2010-05-12 | Janssen Pharmaceutica Nv | PROCESS FOR SYNTHESIS OF IMIDAZOLAMINOIC DERIVATIVES AND RELATED COMPOUNDS |
CN107224675B (en) * | 2016-03-25 | 2023-06-02 | 南京中硼联康医疗科技有限公司 | Boron neutron capture therapy system |
EP3946301A4 (en) * | 2019-04-02 | 2023-08-09 | The University of Chicago | Remodilins for airway remodeling and organ fibrosis |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2285405A1 (en) * | 1997-03-04 | 1998-09-11 | Monsanto Company | Amidoaromatic ring sulfonamide hydroxamic acid compounds |
IL134273A0 (en) * | 1997-07-31 | 2001-04-30 | Procter & Gamble | Acyclic metalloprotease inhibitors |
US6455522B1 (en) * | 1998-02-11 | 2002-09-24 | Bristol-Myers Squibb Pharma Company | Cyclic sulfonamide derivatives as metalloproteinase inhibitors |
AU6542298A (en) * | 1998-03-04 | 1998-09-22 | Monsanto Company | Thioaryl sulfonamide hydroxamic acid compounds |
EP0967201A1 (en) * | 1998-05-20 | 1999-12-29 | Roche Diagnostics GmbH | Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors |
US6566381B1 (en) * | 1999-03-03 | 2003-05-20 | The Procter & Gamble Company | Hetero-substituted metalloprotease inhibitors |
EP1165501A1 (en) * | 1999-03-03 | 2002-01-02 | The Procter & Gamble Company | Alkenyl- and alkynyl-containing metalloprotease inhibitors |
-
2000
- 2000-10-12 KR KR1020027004754A patent/KR20020038951A/en not_active Application Discontinuation
- 2000-10-12 WO PCT/US2000/028194 patent/WO2001027084A1/en not_active Application Discontinuation
- 2000-10-12 AU AU80145/00A patent/AU8014500A/en not_active Abandoned
- 2000-10-12 MX MXPA02003811A patent/MXPA02003811A/en unknown
- 2000-10-12 PL PL00355764A patent/PL355764A1/en not_active Application Discontinuation
- 2000-10-12 SK SK508-2002A patent/SK5082002A3/en not_active Application Discontinuation
- 2000-10-12 TR TR2002/00977T patent/TR200200977T2/en unknown
- 2000-10-12 JP JP2001530105A patent/JP2003519100A/en not_active Withdrawn
- 2000-10-12 BR BR0014759-1A patent/BR0014759A/en not_active IP Right Cessation
- 2000-10-12 HU HU0203118A patent/HUP0203118A3/en unknown
- 2000-10-12 EP EP00970820A patent/EP1224171A1/en not_active Withdrawn
- 2000-10-12 IL IL14889300A patent/IL148893A0/en unknown
- 2000-10-12 CA CA002386485A patent/CA2386485A1/en not_active Abandoned
- 2000-10-12 CZ CZ20021161A patent/CZ20021161A3/en unknown
- 2000-10-12 CN CN00814334A patent/CN1379762A/en active Pending
- 2000-10-12 NZ NZ517983A patent/NZ517983A/en not_active Application Discontinuation
- 2000-10-13 PE PE2000001097A patent/PE20011003A1/en not_active Application Discontinuation
- 2000-10-13 CO CO00078367A patent/CO5271694A1/en not_active Application Discontinuation
-
2002
- 2002-01-01 ZA ZA200202207A patent/ZA200202207B/en unknown
- 2002-04-12 NO NO20021748A patent/NO20021748L/en not_active Application Discontinuation
- 2002-04-12 MA MA26597A patent/MA25561A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL148893A0 (en) | 2002-09-12 |
MA25561A1 (en) | 2002-10-01 |
TR200200977T2 (en) | 2002-08-21 |
MXPA02003811A (en) | 2002-09-30 |
HUP0203118A2 (en) | 2003-01-28 |
CZ20021161A3 (en) | 2002-08-14 |
AU8014500A (en) | 2001-04-23 |
BR0014759A (en) | 2002-07-02 |
NO20021748D0 (en) | 2002-04-12 |
JP2003519100A (en) | 2003-06-17 |
PL355764A1 (en) | 2004-05-17 |
CA2386485A1 (en) | 2001-04-19 |
WO2001027084A1 (en) | 2001-04-19 |
CN1379762A (en) | 2002-11-13 |
NZ517983A (en) | 2004-01-30 |
SK5082002A3 (en) | 2002-10-08 |
ZA200202207B (en) | 2002-12-24 |
HUP0203118A3 (en) | 2003-05-28 |
NO20021748L (en) | 2002-06-14 |
KR20020038951A (en) | 2002-05-24 |
EP1224171A1 (en) | 2002-07-24 |
PE20011003A1 (en) | 2001-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5180578A1 (en) | INHIBITORS OF SUBSTITUTED DIHETER METALOPROTEASES THAT ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS CHARACTERIZED BY THE EXCESSIVE ACTIVITY OF THESE ENZYMES | |
AR012264A1 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION AND METHOD TO OBTAIN THE COMPOSITION TO PREVENT OR AVOID A DISEASE ASSOCIATED WITH UNDESIATED METALOPROTEASICAL ACTIVITY | |
CO4920241A1 (en) | HETERO-CYCLIC METALOPROTEASE INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR ITS USE | |
AR009357A1 (en) | PHOSPHINIC ACID AMIDES COMPOUND AND ITS USES TO PREPARE A PHARMACEUTICAL COMPOSITION AND IN A METHOD TO PREVENT OR TREAT A DISEASE ASSOCIATED WITH METALOPROTEASE ACTIVITY | |
BR9713186A (en) | 1,3-diheterocyclic metalloprotease inhibitors | |
AR002718A1 (en) | HYDROXAMIC ACIDS THAT CONTAIN LACTAMS AND PHARMACEUTICAL COMPOSITION WITH THE SAME. | |
CO4920240A1 (en) | DIHETERO-CYCLIC METALOPROTEASE INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR ITS USE | |
DK0778834T3 (en) | Bicyclic heterocyclic diaryl compounds as inhibitors of cyclooxygenase-2 | |
AR013477A1 (en) | PROSTAGLANDINAS OF REPLACED TETRAHIDRO C16-20 AROMATICO USEFUL AS FP AGONISTS. | |
CO5180642A1 (en) | PIPERIDINE REPLACED COMPOUNDS, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE | |
DE60329316D1 (en) | PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER | |
UY28280A1 (en) | 2- HYDROXI - 3- DIAMINOALCANOS DE BENZAMIDA | |
BR9909620A (en) | Substituted pyrrolidine hydroxamate metalloprotease inhibitors | |
AR009358A1 (en) | METALLOPROTEASE INHIBITOR SPIROCYCLIC COMPOUND | |
BR0008716A (en) | Metalloprotease inhibitors containing alkenyl or alkynyl | |
DE69735090D1 (en) | NEUROTROPHINE ANTAGONIST FOR THE TREATMENT OF EPILEPSIA, ALZHEIMER'S DISEASE AND PAIN | |
CO5420196A1 (en) | INHIBITING COMPOUNDS OF METALOPROTEASE BIDENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR USE | |
CO5150190A1 (en) | NEW ANALOGS OF PROSTAGLANDINA F THAT NATURALLY OCCUR AND METHODS OF USING SUCH NEW ANALOGS OF PROSTAGLANDINA F | |
CO5271694A1 (en) | BETA DI-REPLACED INHIBITORS OF METALOPROTEASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCEDURES FOR APPLICATION | |
CO5160251A1 (en) | ANALOGS OF SELECTED FP C16 RECEIVER PROSTAGLANDINS | |
ES2202156T3 (en) | NEW ANALOGS OF 2-DESCARBOXI-2-PHOSPHINIC PROSTAGLANDINA F. | |
SE0302756D0 (en) | Novel Compounds | |
BR0109328A (en) | Unsubstituted metalloprotease inhibitors containing heterocyclic side chain | |
BR0109348A (en) | Unsubstituted metalloprotease inhibitors which contain carbocyclic side chains | |
NO970340D0 (en) | Organic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |